13D Filing: Discovery Group I, Llc and Entellus Medical Inc (NASDAQ:ENTL)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Discovery Equity Partners 1,857,794 1,857,794 1,857,794 8.5%
Discovery Group I 1,857,794 1,857,794 1,857,794 8.5%

Page 1 of 8 – SEC Filing

UNITED STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington, D.C.
20549

SCHEDULE
13D

(Rule
13d-101)

 

INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO §
240.13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT
TO § 240.13d-2(a)

 

UNDER THE SECURITIES
EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

Entellus
Medical, Inc.
 (Name of Issuer)
Common Stock, par value $0.001 per share
 (Title of Class of Securities)
29363K105
 (CUSIP Number)
Discovery Group I, LLC
300 South Wacker Drive
Suite 600
Chicago, Illinois 60606
Telephone Number: (312) 265-9600
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 27, 2017
(Date of Event which Requires Filing of this Statement)

If the filing person has previously
filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed
in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for
other parties to whom copies are to be sent.

*The remainder of
this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 2 of 8 – SEC Filing

CUSIP No. 29363K105
1. Names of Reporting Persons.
Discovery Equity Partners, L.P.
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
6. Citizenship or Place of Organization
Illinois
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7. Sole Voting Power
None.
8. Shared Voting Power
1,857,794
9. Sole Dispositive Power
None.
10. Shared Dispositive Power
1,857,794
11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,857,794
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
13. Percent of Class Represented by Amount in Row (11)
8.5%
14. Type of Reporting Person (See Instructions)
PN

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 3 of 8 – SEC Filing

CUSIP No. 29363K105
1. Names of Reporting Persons.
Discovery Group I, LLC
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Source of Funds (See Instructions)
AF
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
6. Citizenship or Place of Organization
Delaware
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7. Sole Voting Power
None.
8. Shared Voting Power
1,857,794
9. Sole Dispositive Power
None.
10. Shared Dispositive Power
1,857,794
11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,857,794
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
13. Percent of Class Represented by Amount in Row (11)
8.5%
14. Type of Reporting Person (See Instructions)
IA

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 4 of 8 – SEC Filing

Item 1. Security and Issuer
This Amendment No. 2 to Schedule 13D (“Amendment No. 2”) relates to the Common Stock, par value $0.001 per share (the “Common Stock”), of Entellus Medical, Inc., a Delaware corporation (the “Company”), which has its principal executive offices at 3600 Holly Lane North, Suite 40, Plymouth, MN 55447.  This Amendment No. 2 amends and supplements, as set forth below, the information contained in items 1, 3, 5 and 6 of the Schedule 13D filed by the Reporting Persons with respect to the Company on March 6, 2017, as amended by Amendment No. 1 thereto filed by the Reporting Persons with respect to the Company on March 14, 2017 (as so amended, the “Schedule 13D”).  All capitalized terms used herein but not defined herein have the meanings set forth in the Schedule 13D.  Except as amended by this Amendment No. 2, all information contained in the Schedule 13D is, after reasonable inquiry and to the best of the Reporting Persons’ knowledge and belief, complete and correct as of the date of this Amendment No. 2.
Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended
to read in its entirety as follows:

The total purchase price for the 1,857,794
shares of Common Stock beneficially owned by the Reporting Persons as of March 27, 2017 was approximately $27,969,015. The source
of such funds was the assets of Discovery Equity Partners, including proceeds of margin loans under margin loan facilities maintained
in the ordinary course of business by Discovery Equity Partners with a broker on customary terms and conditions. Discovery Equity
Partners is the legal owner of all of the Common Stock beneficially owned by Discovery Group.

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 5 of 8 – SEC Filing

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended
to read in its entirety as follows:

The information concerning percentages
of ownership set forth below is based on 21,877,702 shares of Common Stock outstanding
as of February 15, 2017 in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2016.

Discovery Equity Partners beneficially
owns 1,857,794 shares of Common Stock as of March 27, 2017, which represents 8.5%
of the outstanding Common Stock.

Discovery Group beneficially owns 1,857,794
shares of Common Stock as of March 27, 2017, which represents 8.5% of the outstanding
Common Stock.

Discovery
Group is the investment manager of Discovery Equity Partners.   Discovery Group exercises ultimate voting and dispositive
power of the securities held by Discovery Equity Partners. As a consequence, Discovery Group may be deemed to share beneficial
ownership of all of the shares of Common Stock owned by Discovery Equity Partners. Voting and disposition decisions at Discovery
Group with respect to the investment of such securities are made by a five-person investment committee (the “Committee”)
which makes such investment decisions by majority vote. No member of the Committee may act individually to vote or sell shares
of Common Stock held by Discovery Equity Partners, nor does any such member have a veto right concerning the vote or sale of any
such common stock. Accordingly, no individual member of the Committee is deemed to beneficially own, and each individual member
of the Committee expressly disclaims beneficial ownership of, within the meaning of Rule 13d-3, any shares of Common Stock held
by Discovery Equity Partners solely by virtue of the fact that he or she is a member of the Committee.

The transactions in Common Stock effected
by the Reporting Persons since those reported in the Schedule 13D filed by the Reporting Persons on March 14, 2017 are set out
in Exhibit 1 hereto.

No person other than Discovery
Equity Partners
is known to any Reporting Person to have the right to receive or the power to direct the receipt of dividends
from, or the proceeds from the sale of, any of the shares of Common Stock reported herein.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended
to read in its entirety as follows:

There
are no contracts, arrangements, understandings or relationships (legal or otherwise) between or among any of the Reporting Persons
and any other person with respect to any securities of the Company other than the governing documents of Discovery Group and Discovery
Equity Partners, the margin loan facilities referred to under Item 3 above, the Joint Filing Agreement of the Reporting Persons
with respect to the Schedule 13D that was included as an exhibit thereto, the Joint Filing Agreement of the Reporting Persons with
respect to this Amendment No. 2 included as Exhibit 2 to this Amendment No. 2, and the Power of Attorney granted by
Michael R. Murphy with respect to reports under Section 13 of the Securities Exchange Act of 1934, as amended, which Power of Attorney
is included as Exhibit 3 to this Amendment No. 2.

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 6 of 8 – SEC Filing

Item 7. Material to Be Filed as Exhibits
Exhibit 1:              List of transactions effected by the Reporting Persons in the Company’s Common Stock since those reported in the Schedule 13D filed by the Reporting Persons on March 14, 2017.
Exhibit 2:             Joint Filing Agreement dated as of March 28, 2017, by and between Discovery Equity Partners and Discovery Group.
Exhibit 3:              Power of Attorney of Michael R. Murphy, dated as of April 28, 2008.

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 7 of 8 – SEC Filing

Signature

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.

March 28, 2017

Date

DISCOVERY EQUITY PARTNERS, L.P.

By: Michael
R. Murphy
*

Signature

Michael R. Murphy, Manager
Name/Title

DISCOVERY GROUP I, LLC

By: Michael
R. Murphy
*

Signature

Michael R. Murphy, Manager
Name/Title
*By: /s/ Mark Buckley

Mark Buckley

Attorney-in-Fact for Michael
R. Murphy

Follow Entellus Medical Inc (NASDAQ:ENTL)

Page 8 of 8 – SEC Filing

Exhibit Index

 

Exhibit 1 List of transactions effected by the Reporting Persons in the Company’s Common Stock since those reported in the Schedule 13D filed by the Reporting Persons on March 14, 2017.
Exhibit 2 Joint Filing Agreement dated as of March 28, 2017, by and between Discovery Equity Partners and Discovery Group.
Exhibit 3 Power of Attorney of Michael R. Murphy, dated as of April 28, 2008.

 

Follow Entellus Medical Inc (NASDAQ:ENTL)